Drug Trial Radar · NCT01909713
Tolerability of a Foaming Facial Cleanser and Moisturizer SPF 30 in a Pediatric Population (7-11) With Acne Prone Skin.
Last checked: Nov 20, 2026Latest source record: Aug 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
35
Actual
Start
May 2013
Primary completion
Jun 2013
Study completion Jun 2013
Sponsor
- Lead sponsor
- Galderma R&DIndustry
- Sponsor type
- Industry
- First posted
- Jul 26, 2013
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 7 years, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the tolerability of Cetaphil® DermaControl™ Foam Wash and Moisturizer SPF 30 in pediatric subjects (7-11) with acne prone skin.
Conditions
- Acne Prone Skin
Interventions
Facial Cleanser and Moisturizer SPF 30Drug
Cetaphil® DermaControl™ Foam Wash and Moisturizer SPF 30
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cutaneous Tolerability Based on Visual Inspection - ErythemaTime frame: Week 3
- Cutaneous Tolerability Based on Visual Inspection - EdemaTime frame: Week 3
- Cutaneous Tolerability Based on Visual Inspection - DrynessTime frame: Week 3
- Cutaneous Tolerability Based on Visual Inspection - RoughnessTime frame: Week 3
Locations
1 site in 1 country. Site status is shown where the registry gives one.
RCTS, Inc.
Irving, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.